France prompts EMA review of combined oral contraceptives
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is looking into whether it is necessary to restrict the use of third and fourth generation combined oral contraceptives to women who cannot take other combined oral contraceptives. The move comes at the behest of French authorities, which have already moved to reduce the use of such products.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.